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Abstract 
Background: Despite increased atherothrombotic risk in type 2 diabetes mellitus, (T2DM) the best preventative 
antithrombotic strategy remains undetermined. We defined the effects of three antiplatelet agents on functional 
readout and biomarker kinetics in platelet activation and coagulation in patients with T2DM.
Materials and methods: 56 patients with T2DM were randomised to antiplatelet monotherapy with aspirin 75 mg 
once daily (OD), clopidogrel 75 mg OD or prasugrel 10 mg OD during three periods of a crossover study. Platelet 
aggregation (PA) was determined by light-transmittance aggregometry and P-selectin expression by flow cytom-
etry. Markers of fibrin clot dynamics, inflammation and coagulation were measured. Plasma levels of 14 miRNA were 
assessed by quantitative polymerase chain reactions.
Results: Of the 56 patients, 24 (43%) were receiving aspirin for primary prevention of ischaemic events and 32 (57%) 
for secondary prevention. Prasugrel was the strongest inhibitor of ADP-induced PA (mean ± SD maximum response 
to 20μmol/L ADP 77.6 ± 8.4% [aspirin] vs. 57.7 ± 17.6% [clopidogrel] vs. 34.1 ± 14.1% [prasugrel], p < 0.001), P-selectin 
expression (30 μmol/L ADP; 45.1 ± 21.4% vs. 27.1 ± 19.0% vs. 14.1 ± 14.9%, p < 0.001) and collagen-induced PA (2 μg/
mL; 62.1 ± 19.4% vs. 72.3 ± 18.2% vs. 60.2 ± 18.5%, p < 0.001). Fibrin clot dynamics and levels of coagulation and 
inflammatory proteins were similar. Lower levels of miR-24 (p = 0.004), miR-191 (p = 0.019), miR-197 (p = 0.009) and 
miR-223 (p = 0.014) were demonstrated during prasugrel-therapy vs. aspirin. Circulating miR-197 was lower in those 
cardiovascular disease during therapy with aspirin (p = 0.039) or prasugrel (p = 0.0083).
Conclusions: Prasugrel monotherapy in T2DM provided potent platelet inhibition and reduced levels of a number 
of platelet-associated miRNAs. miR-197 is a potential marker of cardiovascular disease in this population. Clinical out-
come studies investigating prasugrel monotherapy are warranted in individuals with T2DM.
Trial registration EudraCT, 2009-011907-22. Registered 15 March 2010, https ://www.clini caltr ialsr egist er.eu/ctr-searc h/
trial /2009-01190 7-22/GB.
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Background
Thrombotic events are associated with a large burden 
of morbidity and mortality in the general population 
[1], with an even higher risk in patients with type 2 dia-
betes mellitus (T2DM) [2]. Enhanced platelet activation 
and altered fibrin clot properties are central patho-
logical processes in the development of thrombosis in 
T2DM, thus increasing the risk of cardiovascular events 
and contributing to adverse clinical outcome following 
vascular ischaemia [3–5].
Antiplatelet drugs for the treatment and prevention 
of atherothrombosis have largely focussed on two path-
ways of platelet activation: thromboxane  A2 generation, 
which is blocked by the irreversible cyclo-oxygenase 
inhibitor aspirin, and adenosine diphosphate- (ADP-)
induced amplification of platelet activation via the 
 P2Y12 receptor, which is irreversibly inhibited by thien-
opyridines such as clopidogrel and prasugrel [6]. In 
combination with aspirin, thienopyridines reduce the 
risk of thrombotic events after acute coronary syn-
drome (ACS) [7], but the protective effects can vary 
according to the agent used and the population studied. 
Following coronary ischaemia requiring percutaneous 
intervention, prasugrel has shown enhanced vascu-
lar protective properties compared with clopidogrel in 
T2DM patients without an increase in bleeding risk, in 
contrast to individuals without T2DM [8, 9].
In the clopidogrel vs aspirin in patients at risk of 
ischemic events (CAPRIE) study, clopidogrel, used as 
single antiplatelet therapy (SAPT) showed better pro-
tection against vascular ischaemia compared with aspi-
rin monotherapy in patients with T2DM [10], an effect 
that was even more pronounced in insulin-treated sub-
jects [11]. In contrast to clopidogrel, prasugrel as SAPT 
has not been well studied and data on patients with 
T2DM are scarce.
Studies of aspirin for the primary prevention of car-
diovascular disease in patients T2DM have been disap-
pointing, with little or no reduction in vascular ischaemic 
events at the expense of a significant increase in bleeding 
risk [12–16]. Similarly, the pharmacokinetics and clini-
cal efficacy of clopidogrel, a pro-drug, display significant 
variability between individuals due to differences in activ-
ity of cytochrome P450 2C19 [17]. Prasugrel, whilst also 
a pro-drug, is activated by a different, more predictable 
metabolic pathway and therefore offers better inter-indi-
vidual consistency of effect [18].
In addition to the effects on platelets, aspirin and  P2Y12 
inhibitors may modulate the fibrin network [19, 20] and 
affect vascular inflammatory pathways [21, 22]. In order 
to assess a functional readout and to gain further mech-
anistic insight, platelet function tests have been used to 
assess the response to antiplatelet agents. Micro-rib-
onucleic acids (miRNAs) are emerging as an adjunct to 
our understanding and assessment of platelet function 
[23–25]. From a translational point of view, detection of 
a variety of miRNAs has been linked with clinical out-
comes including ischaemic heart disease [26].
Prasugrel monotherapy in individuals with T2DM may 
offer superior anti-thrombotic properties compared with 
aspirin or clopidogrel. The aim of this study was to com-
prehensively characterise and compare the effects of the 
three drugs on platelet function, fibrin network charac-
teristics, inflammation and expression of miRNAs in a 
cohort of T2DM patients.
Methods
Study design
We performed a single-centre, double-blind, crossover, 
randomised controlled trial of patients with a confirmed 
diagnosis of T2DM. Patients were eligible to participate 
if they were aged 18–75 years, already on treatment with 
aspirin 75 mg once-daily (OD) and able to give informed 
consent. Eligible participants receiving aspirin 75 mg OD 
were randomised 1:1 to one of two medication sequences 
(Fig. 1). All patients continued aspirin 75 mg OD for an 
initial lead-in period of 14 days. One half then received 
clopidogrel 75 mg OD for 28 days then prasugrel 10 mg 
OD for 28 days, whilst the other half received prasugrel 
10 mg OD for 28 days followed by clopidogrel 75 mg OD 
Fig. 1 Design of the study. mg milligrams, OD once daily, R point of randomisation
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for 28 days. Aspirin was discontinued after study comple-
tion if it was deemed clinically unnecessary. Randomisa-
tion was performed by shuffled sealed opaque envelopes 
prepared by a member of pharmacy staff. Both patients 
and investigators were blind to treatment allocation 
until all study data was collected. A range of pharmaco-
dynamic measurements were made at the end of each 
treatment period. The study was approved by the United 
Kingdom National Health Service Research Ethics Ser-
vice (reference 09/H1307/110). Written consent was 
obtained from participants before any study activities 
took place.
Exclusion criteria included: any type of diabetes other 
than T2DM; any coagulation disorder; neoplastic dis-
ease; history of ACS within 3  months of enrolment; 
history of stroke or transient ischaemic attack; history 
of deep venous thrombosis or pulmonary embolism; 
treatment with oral anticoagulant or non-steroidal anti-
inflammatory drugs; abnormal liver enzyme tests defined 
as alanine transferase > threefold upper limit of normal; 
any previous or current upper gastrointestinal pathol-
ogy; weight < 60 kg; and women of child-bearing age and 
refusing to use contraception.
Blood samples
Venous blood samples were collected by venepuncture, 
using syringe and 18G needle, and anticoagulated with 
trisodium citrate dihydrate 3.13%. Platelet-rich plasma 
was prepared by centrifugation for 10 min at 200×g and 
platelet-poor plasma was prepared by further centrifuga-
tion for 10 min at 1500×g. All analyses described below 
were undertaken by individuals blinded to the sample 
details and type of antiplatelet treatment.
Platelet aggregation
Light transmittance aggregometry (LTA) was performed 
using ADP (1, 2, 5, 10 and 20 µmol/L), arachidonic acid 
(AA, 1.0 mmol/L) and collagen (2 and 16 µg/mL) as ago-
nists and a PAP-8 aggregometer (v2.0, Bio/Data Corpo-
ration, Horsham, PA, USA), as previously described [27]. 
Maximum (MA) and final (FA) aggregation responses at 
6 min after agonist injection, adjusted for baseline, were 
recorded. Samples were assessed in duplicate, taking the 
mean value for analysis, and repeated if a discrepancy 
of > 10% was observed between the readings.
Platelet P‑selectin expression
Surface expression of platelet P-selectin after stimulation 
with 0.3, 1, 3, 10 & 30 μmol/L ADP was quantified using 
flow cytometry and expressed as percentage positive 
events, as previously described [28].
Fibrin clot turbidimetric analysis
High-throughput turbidimetric analysis was performed 
as previously described and validated [29–32]. Briefly, 
citrated platelet-poor plasma samples were mixed with 
standard lysis and activation mixes to form acellular 
clots. Serial absorbance was measured using an auto-
mated plate reader during clot formation until lysis was 
achieved. Variables recorded were lag time, representing 
the period from the addition of clot activation mix to the 
start of clot formation (a measure of clotting tendency), 
final clot turbidity (maximum absorbance, a representa-
tion of fibre thickness and clot density), and lysis time 
(time from full clot formation to 50% lysis, a measure of 
fibrinolysis potential).
Coagulation‑associated proteins and inflammatory 
markers
Levels of plasminogen activator inhibitor 1 (PAI1) 
were determined in citrated plasma using enzyme-
linked immunosorbent assay, as previously described 
[32]. Fibrinogen levels were determined by the clotting 
method of Clauss using a KC 10TM coagulometer (Hen-
rich Amelung GmbH, Lemgo, Germany), as described 
elsewhere [33, 34]. Levels of C-reactive protein (CRP) 
and complement C3 were determined, as previously 
described [31].
RNA isolation and miRNA quantification
Quantification of miRNAs with known relevance to 
platelet function and cardiovascular disease (miRs 21, 
24, 27b, 28, 93, 122, 126, 150, 191, 197, 223, 320, 451a 
and 486) was performed in platelet-poor plasma sam-
ples using reverse transcription quantitative polymerase 
chain reaction (RT-qPCR), as previously described [24, 
26]. Total RNA was isolated using the miRNeasy Mini 
kit (Qiagen, Hilden, Germany). In brief, 100 µL of plasma 
were combined with 694.75 µL of QIAzol, 4 µL of diluted 
Caenorhabditis elegans miR-39-3p (cel-miR-39) spike-in 
and 1.25 µL carrier MS2. Following a brief incubation at 
ambient temperature, 140 µL of chloroform were added 
and the solution was mixed vigorously. Samples were 
then centrifuged at 13,500 relative centrifugal force (rcf ) 
for 15  min at 4  °C. The upper aqueous phase was care-
fully transferred to a new tube and 1.5 volumes of etha-
nol were added. The samples were then applied directly 
to columns and washed according to the company’s pro-
tocol. Total RNA was eluted with 35 µL of nuclease-free 
water. A fixed volume of 3 μL of the 35μL RNA eluate 
was used as input for reverse transcription (RT) reac-
tions. MiRNAs were reverse-transcribed using Mega-
plex RT Primer Pools (Human Pool A version 2.1; Life 
Technologies, Darmstadt, Germany) and the TaqMan 
MicroRNA RT kit (Life Technologies, Darmstadt, 
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Germany) according to the manufacturer’s instructions. 
Templates were pre-amplified using Megaplex PreAmp 
Primers (Primers A version 2.1) and PreAmp Mastermix 
(Life Technologies) with 12 cycles of 95  °C for 15  s and 
60 °C for 4 min. Pre-amplification product was 72 times 
diluted and 2.25 μL were combined with 0.25 μL TaqMan 
microRNA assay (20×) (Life Technologies) and 2.5 μL 
TaqMan Universal PCR Master Mix No AmpErase UNG 
(2×) to a final volume of 5 μL. RT-qPCR was performed 
on an Applied Biosystems Viia 7 thermocycler at 95  °C 
for 10  min, followed by 40 cycles of 95  °C for 15  s and 
60 °C for 1 min. Clinical data were blinded to laboratory 
personnel.
Cel-miR-39 was used for normalisation and as a qual-
ity control. Quantification results were calibrated with 
pooled RNA from 50 samples. Quantification cycle (Cq) 
values > 32 were considered to fall below the limit of 
detection. Relative quantification was performed with 
Microsoft Excel, version 15.32 for Mac using the  2(−∆∆Cq) 
method [35].
Statistical analysis
The three treatments were compared by repeated meas-
ures ANOVA with Greenhouse–Geisser correction. The 
primary endpoints of the study were platelet aggregation 
responses to ADP, collagen and AA; platelet P-selectin 
expression and fibrin clot dynamics. Other analyses were 
exploratory. For variables with a significant difference 
(p < 0.05) between the treatments, pairwise comparisons 
were performed using Bonferroni correction. SPSS sta-
tistics v25 (IBM software) was used for these analyses 
and graphical representations generated using GraphPad 
PRISM v7. Correlation and subgroup analyses were per-
formed using RStudio v1.1.456: adjustment for multiple 
comparisons was not made for these as they were explor-
atory and intended for hypothesis generation.
A total of 56 patients were needed to detect a 10% dif-
ference in platelet aggregation response to various ago-
nists comparing the different therapies at p < 0.05 and 
90% power, based on the assumption that the common 
standard deviation of the response variable is 16%. The 
study also had the power to detect a 7% difference in clot 
final turbidity based on the assumption that standard 
deviation for the response variable is 11% (p < 0.05, 90% 
power).
Results
Recruitment and participant characteristics
Of 310 patients who were approached, 64 were enrolled 
and 56 completed the study (Additional file 1: Figure S1). 
Baseline characteristics are shown in Table 1.
Table 1 Baseline characteristics of  participants completing 
the study
Participants (n = 56)
Sex
 Female/male 9/47
Age (years)
 Mean (range) 60.7 (46–73)
Smoking (Y/N) 11/45
Blood pressure [mean ± SD]
 Systolic (mmHg) 132.0 ± 16.32
 Diastolic (mmHg) 80.0 ± 9.51
Physical examination [mean ± SD]
 Height (m) 1.72 ± 0.07
 Weight (kg) 96.18 ± 17.60
 BMI 32.70 ± 5.23
Baseline blood tests [mean ± SD]
 HbA1c (mmol/mol) 71.60 ± 22.99
 Sodium (mmol/L) 139.28 ± 2.39
 Potassium (mmol/L) 4.48 ± 0.39
 Creatinine (μmol/L) 83.13 ± 20.66
 Urea (mmol/L) 6.20 ± 2.41
 eGFR (mL/min/1.73 m2) 80.70 ± 13.24
 Total cholesterol (mmol/L) 3.79 ± 0.77
 LDL (mmol/L) 1.89 ± 0.49
 HDL (mmol/L) 1.08 ± 0.26
 Triglycerides (mmol/L) 2.06 ± 2.01
 FT4 (pmol/L) 15.10 ± 2.12
 TSH (mIU/L) 2.00 ± 1.12
History of macrovascular disease 32 (57%)
Microvascular complications
 Retinopathy 23 (41%)
 Nephropathy 9 (16%)
 Neuropathy 15 (27%)
Concomitant medication and therapies
 Diabetes related
  Metformin 48 (86%)
  Sulphonylurea 15 (27%)
  Gliptin 6 (11%)
  Glitazone 5 (9%)
  GLP-1 analogues 5 (9%)
  SGLT2-inhibitors 0 (0%)
  Insulin 27 (48%)
 Antihypertensives
  ACE inhibitor/ARB 48 (86%)
  Calcium channel blocker 13 (23%)
  Diuretic 16 (29%)
  Beta-blockers 26 (47%)
  Αlpha-blockers 5 (9%)
 Lipid-lowering
  Statin 52 (93%)
  Fibrate 1 (2%)
  Ezetimibe 7 (13%)
ARB angiotensin receptor blocker, FT4 free thyroxine, GLP-1 glucagon like 
peptide 1, SGLT2 sodium-glucose transporter 2, TSH thyroid stimulating 
hormone
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Platelet aggregation responses
Maximum aggregation (MA) responses are summarised 
in Tables  2, 3 and Fig.  2a. Between the 3 treatments, 
there were significant differences in MA responses to 
all the agonists and concentrations tested (all p < 0.001). 
ADP-induced platelet aggregation, at all 5 concentrations 
tested, was significantly greater when receiving aspirin 
compared to clopidogrel (all p < 0.001) and clopidogrel 
compared to prasugrel (all p < 0.001). In contrast, platelet 
aggregation responses to 1 mmol/L AA were significantly 
lower when receiving aspirin (6.6 ± 19.0%) compared 
to clopidogrel (63.4 ± 34.6%, p < 0.001) and prasugrel 
(52.6% ± 31.1%, p < 0.001). The difference between clopi-
dogrel and prasugrel was also significant (p = 0.027). The 
response to collagen 2 μg/mL was significantly reduced 
when receiving aspirin (62.1 ± 19.4%) compared to clopi-
dogrel (72.3 ± 18.2%, p = 0.001), while prasugrel-treated 
individuals had a similar response to those on aspirin 
(60.2 ± 18.5%, p > 0.99). The response to collagen 16 μg/
mL was similar when receiving aspirin (84.4 ± 7.0%) com-
pared to clopidogrel (83.8 ± 8.1%, p > 0.99) but was lower 
when receiving prasugrel (78.6 ± 9.4%, p < 0.001). Com-
pared to prasugrel, responses to both 2 and 16 μg/mL 
collagen were more pronounced when receiving clopi-
dogrel (p < 0.001 and 0.003 respectively). FA responses 
followed a similar pattern (data not shown).
Comparing platelet aggregation responses when receiv-
ing standard-of-care aspirin 75  mg OD to those at the 
end of the study aspirin period, there were no differences 
(Additional file 1: Table S1).
High residual platelet reactivity
High on-treatment residual platelet reactivity (HRPR), 
which has been associated with increased ischaemic 
Table 2 Results of study endpoints relating to platelet function, P-selectin expression, fibrin clot dynamics, coagulation-
associated proteins and inflammatory markers
p values represent a repeated-measures ANOVA conducted between the three treatments
AA arachidonic acid, C3 complement fragment 3, PAI-1 plasminogen activator inhibitor 1, WCC white cell count
Aspirin (n = 56) Clopidogrel (n = 56) Prasugrel (n = 56) p
Mean ± SD Mean ± SD Mean ± SD
Maximum platelet aggregation response (%)
Agonist [Agonist]
 ADP 1 μmol/L 42.7 ± 15.6 22.3 ± 12.9 11.5 ± 8.1 < 0.001
2 μmol/L 61.0 ± 12.4 37.9 ± 17.0 21.0 ± 11.4 < 0.001
5 μmol/L 71.0 ± 8.9 49.2 ± 17.0 27.9 ± 12.8 < 0.001
10 μmol/L 80.5 ± 9.7 58.2 ± 18.1 33.6 ± 14.3 < 0.001
20 μmol/L 77.6 ± 8.4 57.7 ± 17.6 34.1 ± 14.1 < 0.001
 AA 1 mmol/L 6.6 ± 19.0 63.4 ± 34.6 52.6 ± 31.1 < 0.001
 Collagen 2 μg/mL 62.1 ± 19.4 72.3 ± 18.2 60.2 ± 18.5 < 0.001
16 μg/mL 84.4 ± 7.0 83.8 ± 8.1 78.6 ± 9.4 < 0.001
Platelet P-selectin expression (%)
[ADP] (μmol/L)
 0.3 18.4 ± 13.0 12.5 ± 10.4 5.9 ± 5.0 < 0.001
 1 31.2 ± 19.0 18.2 ± 14.5 9.0 ± 6.8 < 0.001
 3 37.8 ± 23.1 23.5 ± 17.3 10.4 ± 7.7 < 0.001
 10 41.5 ± 23.7 24.2 ± 17.6 11.5 ± 8.1 < 0.001
 30 45.1 ± 21.4 27.1 ± 19.0 14.1 ± 14.9 < 0.001
Fibrin clot dynamics
 Lag time (s) 683.3 ± 170.4 706.9 ± 196.2 665.0 ± 151.8 0.007
 Maximum absorbance (AU) 0.2 ± 0.08 0.2 ± 0.09 0.2 ± 0.08 0.65
 Lysis time (s) 519.6 ± 112.3 522.3 ± 132.8 522.4 ± 101.2 0.95
Coagulation-associated proteins
 Fibrinogen (g/L) 2.8 ± 0.5 2.7 ± 0.5 2.7 ± 0.5 0.69
 PAI-1 (pg/mL) 2334.6 ± 1675.3 2132.5 ± 1626.4 2089.3 ± 1667.1 0.27
Inflammatory markers
 WCC (×106/L) 7.2 ± 1.8 6.7 ± 1.9 7.0 ± 2.0 0.067
 CRP (mg/L) 2.3 ± 3.4 2.4 ± 4.6 1.8 ± 2.2 0.5
 C3 (g/L) 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.27
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risk, can be defined based on a maximum aggregatory 
response to 20 μmol/L ADP of > 59%, when assessed by 
LTA [36–38]. In this study, whilst receiving aspirin, all 
participants had HRPR. The proportion was reduced 
compared to aspirin when receiving either clopidogrel 
(relative risk [RR] 0.54, 95% CI [0.41–0.66], p < 0.0001) 
or prasugrel (RR 0.05 [0.02–0.15], p < 0.0001), and when 
receiving prasugrel compared to clopidogrel (RR 0.1 
Table 3 Pairwise comparisons (with Bonferroni correction) for  those endpoints with  significant differences 
between the three treatments on ANOVA
AA arachidonic acid
Aspirin vs. clopidogrel Aspirin vs. prasugrel Clopidogrel vs. prasugrel
Mean difference (95% CI) p Mean difference (95% CI) p Mean difference (95% CI) p
Maximum platelet aggregation response (%)
Agonist Concentration
 ADP 1 μmol/L 20.46 (16.33 to 24.58) < 0.001 31.24 (26.79 to 35.68) < 0.001 10.78 (7.34 to 14.22) < 0.001
2 μmol/L 23.04 (17.17 to 29.91) < 0.001 39.96 (35.75 to 44.18) < 0.001 16.93 (12.48 to 21.00) < 0.001
5 μmol/L 21.80 (16.01 to 27.59) < 0.001 43.07 (38.54 to 47.60) < 0.001 21.27 (16.75 to 25.80) < 0.001
10 μmol/L 22.29 (15.97 to 28.61) < 0.001 46.86 (41.39 to 52.32) < 0.001 24.56 (28.98 to 20.14) < 0.001
20 μmol/L 19.94 (13.71 to 26.14) < 0.001 43.53 (38.57 to 48.49) < 0.001 23.60 (19.34 to 27.83) < 0.001
 AA 1 mmol/L − 56.86 (− 68.89 to − 44.82) < 0.001 − 45.98 (− 56.77 to − 35.20) < 0.001 10.87 (0.95 to 20.79) 0.027
 Collagen 2 μg/mL − 10.24 (− 16.52 to − 3.95) 0.001 1.86 (− 3.22 to 6.92) > 0.99 12.09 (7.52 to 16.66) < 0.001
16 μg/mL 0.62 (− 2.28 to 3.52) > 0.99 5.73 (2.71 to 8.74) < 0.001 5.11 (1.48 to 8.74) 0.003
Platelet P-selectin expression (%)
[ADP] μmol/L
 0.3 5.87 (2.05 to 9.69) 0.001 12.52 (8.32 to 16.72) < 0.001 6.65 (3.65 to 9.65) < 0.001
 1 13.00 (6.56 to 19.43) < 0.001 22.23 (16.00 to 28.45) < 0.001 9.23 (5.30 to 13.16) < 0.001
 3 14.27 (6.95 to 21.58) < 0.001 27.37 (19.63 to 35.11) < 0.001 13.10 (8.19 to 18.01) < 0.001
 10 17.28 (9.90 to 24.66) < 0.001 29.95 (22.17 to 37.74) < 0.001 12.67 (7.55 to 17.80) < 0.001
 30 18.02 (9.82 to 26.22) < 0.001 30.97 (23.13 to 38.81) < 0.001 12.95 (7.22 to 18.68) < 0.001
Fibrin clot dynamics
 Lag time (s) − 23.61 (− 56.2 to 8.98) 0.237 18.28 (− 8.57 to 45.12) 0.295 41.8 (7.41 to 76.37) 0.012
Fig. 2 a Maximum platelet aggregation responses assessed by light transmittance aggregometry. AA arachidonic acid; b proportions of 
participants during each treatment period with high (HRPR) and low residual platelet reactivity (LRPR), defined as a maximum aggregation response 
to 20 μmol/L ADP of > 59% and ≤ 59% respectively
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[0.03–0.28], p < 0.0001) (Additional file  1: Table  S2, 
Fig. 2b).
Platelet P‑selectin expression
Measurement of ADP-stimulated platelet P-selectin 
expression revealed significant differences between the 
3 treatments at all concentrations of ADP used (e.g. 30 
μmol/L: aspirin 45.1 ± 21.4% vs. clopidogrel 27.1 ± 19.0% 
vs. prasugrel 14.1 ± 14.9%, p < 0.001) (Table  2, Fig.  3). 
On pairwise comparison, expression was significantly 
greater when treated with clopidogrel vs. aspirin, prasug-
rel vs. aspirin and prasugrel vs. clopidogrel (all p ≤ 0.001) 
(Table 3, Fig. 3).
Fibrin clot properties
Lag time was significantly different when comparing aspi-
rin, clopidogrel and prasugrel treatment (683.3 ± 170.4 s 
vs. 706.9 ± 196.2  s vs. 665.0 ± 151.8  s, respectively, 
p = 0.007 [ANOVA]) (Table  2, Additional file  1: Figure 
S1). There was no difference between aspirin and clopi-
dogrel (p = 0.24), nor aspirin and prasugrel (p = 0.30), but 
lag time was significantly longer when receiving clopi-
dogrel vs. prasugrel (p = 0.012) (Table 3, Additional file 1: 
Figure S2). There were no significant differences between 
the treatments in final clot turbidity (0.2 ± 0.08 (arbi-
trary units) vs. 0.2 ± 0.09 vs. 0.2 ± 0.08, p = 0.65) or lysis 
time (519.6 ± 112.3 s vs. 522.3 ± 132.8 s vs. 522.4 ± 101.2, 
p = 0.95) (Table 2, Additional file 1: Figure S3). Lysis time, 
but not other parameters, significantly correlated with 
 HbA1c (R = 0.18, p = 0.027) (Additional file 1: Table S3).
Coagulation factors and inflammatory markers
No significant differences in fibrinogen, circulating leu-
kocyte count, CRP or complement C3 were observed 
between the treatments (all p > 0.05, Table 2).
MiRNA quantification
Significant differences were seen between the treatments 
in circulating levels of miR-21, miR-24, miR-191, miR-
197 and miR-223 (Table 4, Fig. 4). Post-hoc pairwise com-
parisons revealed significantly lower miRNA expression, 
when receiving prasugrel compared to aspirin, of miR-24 
(p = 0.004), miR-191 (p = 0.019), miR-197 (p = 0.009) and 
miR-223 (p = 0.014), but not miR-21 (p = 0.10 (Table  5, 
Fig.  5). There were no significant differences in miRNA 
levels between aspirin and clopidogrel nor between 
clopidogrel and prasugrel.
Correlation between miRNA detection and other markers
Platelet ADP-stimulated P-selectin expression cor-
related with circulating levels of miR-21 (R = 0.23, 
p = 0.003), miR-24 (R = 0.22, p = 0.004), miR-191 
(R = 0.2, p = 0.008) and miR-223 (R = 0.25, p = 0.002), 
but not miR-197 (R = 0.12, p = 0.13) (Fig. 5, Additional 
file  1: Table  S3). Conversely, there was a negative cor-
relation between AA-induced platelet aggregation 
and levels of miR-24 (R = − 0.21, p = 0.004), miR-191 
(R = − 0.20, p = 0.01), miR-197 (R = − 0.23, p = 0.002) 
and miR-223 (R = − 0.24, p = 0.002) but not miR-21 
(R = -0.08, p = 0.30) (Additional file  1: Table  S3). No 
significant correlations were observed between ADP- or 
collagen-induced platelet aggregation and circulating 
miRNA levels (Additional file 1: Table S3).
Of the fibrin clot parameters studied, there was a sig-
nificant positive correlation between final clot turbidity 
Fig. 3 Platelet P-selectin expression in response to stimulation with 
ADP at concentrations of 0.3, 3 and 30 μmol/L
Table 4 Levels of  circulating miRNAs in  patients 
with  diabetes receiving aspirin, clopidogrel or  prasugrel. 
Values shown are mean ± SD. P values were generated 
by one-way repeated measures ANOVA with Greenhouse–
Geisser correction
miR 2−(ΔΔCq) (mean ± SD) p Partial η2 
(effect size)
Aspirin Clopidogrel Prasugrel
21 1.21 ± 0.67 1.04 ± 0.51 1.03 ± 0.47 0.028 0.065
24 1.05 ± 0.64 0.88 ± 0.70 0.75 ± 0.40 0.009 0.084
27b 1.09 ± 0.79 0.96 ± 1.22 0.75 ± 0.38 0.115 0.042
28 0.83 ± 0.54 0.65 ± 0.53 0.63 ± 0.60 0.083 0.046
93 1.06 ± 0.60 0.95 ± 0.74 1.01 ± 0.78 0.662 0.007
122 0.93 ± 0.82 0.98 ± 0.98 1.07 ± 1.00 0.278 0.023
126 0.93 ± 0.42 0.83 ± 0.47 0.80 ± 0.34 0.110 0.057
150 0.83 ± 0.34 0.81 ± 0.43 0.80 ± 0.36 0.777 0.004
191 0.87 ± 0.65 0.66 ± 0.62 0.59 ± 0.48 0.017 0.073
197 1.13 ± 0.68 0.97 ± 0.82 0.82 ± 0.45 0.019 0.072
223 0.93 ± 0.55 0.78 ± 0.50 0.70 ± 0.41 0.014 0.076
320 0.93 ± 0.46 0.82 ± 0.46 0.79 ± 0.40 0.087 0.045
451a 1.04 ± 0.65 0.95 ± 0.43 1.20 ± 0.99 0.165 0.034
486 0.96 ± 0.70 0.85 ± 0.45 1.11 ± 1.17 0.215 0.028
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and miR-21 (R = 0.22, p = 0.006, Additional file  1: Fig-
ure S3) but no other parameters, nor with other miR-
NAs (Additional file  1: Table  3). Subgroup analysis of 
levels miR-21, miR-24, miR-191, miR-197 and miR-
223 by HRPR status revealed no significant differences 
between the groups (Additional file 1: Table S4).
miR‑126
Although levels of miR-126 have been linked to platelet 
and endothelial function in the general population [25], 
T2DM may be associated with lower detectable quan-
tities [39]. P-selectin expression in response to ADP 
stimulation showed positive correlation with miR-126 
(R = 0.27, p = 0.0004) (Additional file  1: Table  S3, Addi-
tional file 1: Figure S4). On the other hand, we failed to 
show significant differences in quantification of miR-126 
between the treatments and there was no evidence of a 
significant correlation between aggregation responses 
and miR-126 (Additional file 1: Table S2).
Effect of presence or absence of cardiovascular disease
Subgroup analysis by presence (n = 32) or absence 
(n = 24) of a history of macrovascular atheromatous dis-
ease (history of coronary artery disease, cerebrovascular 
ischaemia or peripheral arterial disease) at enrolment 
revealed no significant differences between the sub-
groups in markers of platelet aggregation during each of 
the three treatment periods (Additional file 1: Table S5). 
Of the five miRNAs identified as having different expres-
sion profiles across the treatments, levels of miR-197 
were significantly lower in those with cardiovascular 
disease compared to those without when receiving aspi-
rin (0.97 ± 0.63 vs. 1.35 ± 0.69, p = 0.04) and prasugrel 
(0.68 ± 0.33 vs. 0.99 ± 0.46, p = 0.008), but not clopidogrel 
(0.85 ± 0.78 vs. 1.15 ± 0.89, p = 0.2) (Additional file  1: 
Table  S5, Fig.  6). There were no significant differences 
between quantification of other miRNAs and cardiovas-
cular disease state (Additional file 1: Table S5), including 
miR-126 (Additional file 1: Figure S6).
Fig. 4 Quantification of plasma levels of miR-21, miR-24, miR-126, miR-191, miR-197 and miR-223 using the  2−ΔΔcq method, expressed relative to 
the mean value when receiving aspirin
Table 5 Pairwise comparisons (with Bonferroni correction) for  those miRNAs with  significant differences 
between the three treatments on ANOVA
CI confidence interval
miR‑ Aspirin vs. clopidogrel Aspirin vs. prasugrel Clopidogrel vs. prasugrel
Mean difference (95% CI) p Mean difference (95% CI) p Mean difference (95% CI) p
21 0.17 (− 0.004 to 0.345) 0.058 0.177 (− 0.023 to 0.378) 0.100 0.007 (− 0.158 to 0.172) > 0.99
24 0.165 (− 0.069 to 0.398) 0.262 0.295 (0.081 to 0.510) 0.004 0.131 (− 0.116 to 0.377) 0.586
191 0.208 (− 0.031 to 0.446) 0.108 0.272 (0.036 to 0.508) 0.019 0.064 (− 0.185 to 0.313) > 0.99
197 0.153 (− 0.138 to 0.444) 0.596 0.311 (0.065 to 0.558) 0.009 0.158 (− 0.102 to 0.418) 0.416
223 0.146 (− 0.052 to 0.343) 0.220 0.226 (0.036 to 0.416) 0.014 0.08 (− 0.103 to 0.263) 0.852
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Discussion
Patients with T2DM present particular challenges with 
regards to atherothrombotic protection. There is no 
current clear strategy of antiplatelet therapy for pri-
mary prevention in those with T2DM. For example, 
whilst some evidence suggests that aspirin therapy tar-
geted by assessment of cardiovascular and bleeding risk 
may be of benefit [40], guidelines remain conflicted on 
the extent to which, if at all, aspirin therapy should be 
recommended in this situation [41, 42].  P2Y12 inhibi-
tors are alternative antiplatelet agents to aspirin with 
the potential benefits of prolonged presence in the 
plasma that might overcome reduced aspirin effect due 
to high platelet turnover and avoiding gastric erosion 
[43]. Three orally-active drugs, clopidogrel, prasugrel 
and ticagrelor are commonly-available [6]. Monother-
apy with clopidogrel offers only modest clinical bene-
fits over aspirin in the setting of secondary prevention, 
but these may be amplified in those with T2DM [11]. 
Furthermore, the newer  P2Y12 inhibitors ticagrelor and 
prasugrel are more potent and consistent in effect than 
clopidogrel [44]. Certainly, when given in combination 
with aspirin, ticagrelor and prasugrel offer net clini-
cal benefit after ACS [6]. Additionally, there is evi-
dence that potent  P2Y12 inhibition may offer benefits in 
Fig. 5 Correlation between platelet P-selectin expression, after stimulation with 30 μmol/L ADP, and relative quantity of a miR-21, b miR24, c 
miR-191 and d miR-223. Dark blue lines indicate those of best linear fit, light blue shading indicates 95% confidence interval. R and p values were 
produced by Pearson correlation analysis
Fig. 6 Relative quantification of circulating miR-197 in participants 
with and without a history of cardiovascular disease during the three 
treatment periods. Large dots and lines represent mean ± SD. p 
values were generated by t-tests
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patients with T2DM and complications such as lower 
extremity arterial disease, in which ticagrelor improves 
microvascular flow, for example [45]. Although there 
has been concern over greater bleeding risk increasing 
the potency of  P2Y12 inhibition, recent evidence sug-
gests, for example, ticagrelor may have similar safety 
to clopidogrel in patients at high risk of bleeding, such 
as those who are elderly with ST-elevation myocardial 
infarction [46], and low-dose prasugrel appears to be 
of comparable safety to clopidogrel when used in triple 
therapy (aspirin,  P2Y12 inhibitor and anticoagulant) for 
patients with atrial fibrillation undergoing percutane-
ous coronary intervention [47].
In this study, we have comprehensively character-
ised the effects of aspirin, clopidogrel and prasugrel 
when given as SAPT to patients with T2DM. Prasugrel 
provided the strongest effect on ADP-induced platelet 
aggregation, as did aspirin on AA-induced aggregation. 
Prasugrel also provided greater and more consistent inhi-
bition of ADP-induced platelet aggregation when com-
pared to clopidogrel, in agreement with previous studies 
on populations with and without diabetes receiving dual 
antiplatelet therapy [44, 48] and of studies of prasugrel 
vs. clopidogrel loading doses when given as SAPT [49]. 
In concert with this was the fact that there was a large 
reduction in the proportion of patients with HRPR when 
receiving clopidogrel vs. aspirin, and again when receiv-
ing prasugrel vs. either comparator. P-selectin expression 
after stimulation with ADP followed a similar pattern 
to the aggregation responses. Collagen-induced platelet 
aggregation, perhaps representing the best global assess-
ment of effects on platelet macroaggregation, was more 
strongly inhibited by prasugrel than aspirin and clopi-
dogrel, suggesting that prasugrel acts as the most potent 
antiplatelet drug of the three when used as monotherapy 
in patients with T2DM.
For the first time, we studied a panel of miRNAs in 
patients with diabetes receiving three different anti-
platelet agents, showing that potent  P2Y12 inhibition 
with prasugrel reduced detectable levels of miR-24, 
miR-191, miR-197 and miR-223 compared to aspirin. 
Although there were no significant differences between 
aspirin and clopidogrel nor clopidogrel and prasug-
rel, there did appear to be similar trends; thienopyri-
dines reduced miRNA levels, an effect that was most 
pronounced with prasugrel. The known actions and 
associations of miRNAs are broad-ranging, but circu-
lating levels of miR-21, miR-24, miR-197 and miR-223 
are most strongly associated with platelets and platelet 
microparticles, along with miR-126 [26]. These, as well 
as miR-191, have been shown to be reduced by anti-
platelet therapy in healthy volunteers, and some also 
in patients with cardiovascular disease [24, 25]. Our 
study, in individuals with T2DM, supports the associa-
tion between plasma levels of these miRNAs and platelet 
function.
Whilst there were positive correlations between 
miRNA levels and ADP-induced platelet P-selectin 
expression, there was no evidence of a significant corre-
lation with ADP or collagen-induced aggregation, and 
we observed negative correlations with AA-induced 
aggregation in some cases. P-selectin expression, which 
is known to be reduced by  P2Y12 inhibitors but not 
aspirin [28], occurs when alpha granules fuse with the 
cell membrane upon platelet activation. These data 
suggest that plasma levels of miRNAs reflect primar-
ily the tendency for platelet degranulation and indeed 
it has previously been shown that miRNAs may be 
involved in regulating degranulation [50]. This has 
not been reported before in individuals with diabetes 
receiving antiplatelet therapy and future research is 
required to understand the specific role of each of the 
miRNAs, which may help with risk stratification and/or 
uncover alternative therapeutic targets to control plate-
let activation in this population.
We saw lower plasma quantities of miR-197 in T2DM 
patients with known cardiovascular disease compared to 
those without, which is consistent with the previous find-
ing in a general population cohort suggesting that lower 
miR-197 might be associated with increased risk of myo-
cardial infarction [26, 51]. In contrast to previous findings 
in the general population, we did not see evidence of an 
association between elevated levels of miR-126 and pres-
ence of cardiovascular disease. Notably, however, studies 
have suggested that T2DM itself is associated with lower 
detectable quantities of miR-126 and therefore its prog-
nostic significance as a vascular marker is potentially lost 
in the presence of diabetes and this may further explain 
the failure to demonstrate a treatment effect [39].
Conclusion
In summary, our data suggest that prasugrel monother-
apy is superior to either aspirin or clopidogrel in inhib-
iting platelet function in diabetes. From a translational 
perspective these findings could have the potential to 
be implemented in personalised treatment options for 
patients with T2DM and cardiovascular disease. Moreo-
ver, our miRNA results indicate that assessing response 
to antiplatelet therapy does not necessarily require fresh 
blood samples and tests can be conducted on miRNA 
measurements as biomarkers from stored acellular 
plasma samples. miRNA measurements may provide 
a platform to identify patients at greater risk of ischae-
mic heart disease relating to their platelet function. 
Based on these data and acknowledging that platelet 
activation is the central process in the development of 
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atherothrombosis, a trial assessing the effects on clinical 
outcomes of prasugrel monotherapy may be warranted 
for the primary or secondary prevention of ischaemic 
heart disease in patients with T2DM. Also, further ana-
lysing the role of miRNA in predicting vascular outcome 
in individuals with diabetes may offer a tool to measure 
the clinical efficacy of antiplatelet agents.
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